Status:
COMPLETED
Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Conditions:
Metastatic Sporadic Medullary Thyroid Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Vandetanib has been approved for patients with unresectable and/or metastatic medullary thyroid cancer (MTC) by the Food and Drug Administration, by the European Medicines Agency and, very recently, i...
Detailed Description
Medullary thyroid cancer (MTC) is considered worldwide a rare cancer. It derives from the parafolicular C-cells representing about 5-10% of all thyroid cancer. MTC is diagnosed as sporadic form (sMTC)...
Eligibility Criteria
Inclusion
- diagnosis of sMTC surgically treated (total thyroidectomy)
- locally relapsed and or metastatic sMTC
- metastatic MTC never treated with TKI before (valid for subjects treated with vandetanib only, in whom we will investigate the variation of circulating miRNA profile before and after vandetanib administration).
Exclusion
- Patients with severe infection, active clinical co-morbidities, or a history of any other malignancy have been excluded.
Key Trial Info
Start Date :
April 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT02268734
Start Date
April 1 2014
End Date
December 1 2018
Last Update
September 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Milan, Italy, 20133